Waiting
Elaborazione accesso...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Bioengineering / High-Throughput Cardiotoxicity Screening Using…
JoVE Journal
Bioengineering

È necessario avere un abbonamento a JoVE per visualizzare questo Contenuto. Accedi o inizia la tua prova gratuita.

JoVE Journal Bioengineering
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
 

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Article DOI: 10.3791/64364-v • 14:03 min • March 24th, 2023
March 24th, 2023 •
1, 2, 3, 1, 1
1Frankel Cardiovascular Regeneration Core Laboratory, Cardiovascular Medicine-Internal Medicine, University of Michigan, Ann Arbor, 2CAIRN Research, 3StemBioSys, Inc.

Capitoli

Riepilogo
Automatic Translation

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer an alternative to using animals for preclinical cardiotoxicity screening. A limitation to the widespread adoption of hiPSC-CMs in preclinical toxicity screening is the immature, fetal-like phenotype of the cells. Presented here are protocols for robust and rapid maturation of hiPSC-CMs.

Tags

Keywords: HiPSC-CM Cardiotoxicity Screening High-throughput Mature Cardiomyocytes Extracellular Matrix EP Assay MACS
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter